Lymph node type as a prognostic factor for survival in T2 N1 M0 non-small cell lung carcinoma

Prognostic factors in resected pathological N1-stage II nonsmall cell lung cancer

“…Although the N descriptors in the new edition of TNM system were not changed, several studies have reported that, within the N1 category, there are several prognostic modifiers. These include the number of lymph nodes involved (solitary versus multiple) [19][20][21], the ratio of lymph nodes involved [20,21], the level of lymph nodes involved (hilar versus lobar) [7,11,12,22,23], and the pattern of lymph nodes involved (direct invasion versus separate metastases) [24,25]. Several studies have highlighted that N1 disease represents a heterogeneous group of patients with different lymph node-related factors affecting prognosis.…”

“…VAN VELZEN et al [11] reported that the presence of VPI unfavourably affected survival in T2N1M0 NSCLC patients (p50.0093). However, in the study by RIQUET et al [12], VPI did not correlate with overall survival in pathological N1 NSCLC patients (p50.65).…”

“…In recent decades, many authors have suggested that within the subset of patients with pathological N1 disease, the prognosis may differ according to the number, level or type of lymph nodes involved [8][9][10][11][12][13][14]. Stage II NSCLC included a relatively smaller number of patients compared with those with stage I NSCLC.…”

Impact of main bronchial lymph node involvement in pathological T1-2N1M0 non-small-cell lung cancer: multi-institutional survey by the Japan National Hospital Study Group for Lung Cancer

“…[6][7][8][9][10][11] Metastases to the hilar, interlobar, or both lymph nodes have been associated with a poorer prognosis compared with metastasis to the intralobar lymph nodes. Studies published since 2000 that refer to main bronchial lymph node involvement are summarized in Table 5.…”

“…2 In addition to those with N2 disease, [3][4][5] there is a heterogeneous group of patients who present with involvement of the N1 nodes. [6][7][8][9][10][11] To devise benefi cial therapeutic strategies, it is considered important to distinguish the subgroups with good or poor prognosis among N1 patients. However, at present, two different lymph node maps are utilized: the Naruke map used in Japan and some other countries 12 and the Mountain-Dresler (M-D) map, which is used in most areas of the world.…”